Leukemia - Table of Contents alert Volume 32 Issue 9

If you are unable to see the message below, click here to view.

Advertisement See how droplets are guiding precision medicine  Liquid biopsy promises a new level of precision in disease profiling and drug resistance monitoring. Is your lab using this tool to its full potential? See how a promising new technology lets you give clinicians insights that can guide personalized cancer treatments.   TABLE OF CONTENTS Volume 32, Issue 9 In this issue Review Article Article Brief Communication Correspondence Also new AOP   Advertisement   Now Enrolling - Clinical studies for oral pracinostat in Acute Myeloid Leukemia (AML) Patients Unfit for Induction Chemotherapy and in Myelodysplastic Syndromes (MDS) trials Pracinostat is an investigational agent not approved for commercial use by the FDA or any other regulatory agency worldwide PRAN-US-0024   Review Article European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias Maria Gavriatopoulou, Pellegrino Musto, Jo Caers, Giampaolo Merlini, Efstathios Kastritis et al. Leukemia 2018 32 :1883 - 1898; July 23, 2018; 10.1038/s41375-018-0209-7   Abstract | Full Text Targeting Bcl-2 for the treatment of multiple myeloma Cyrille Touzeau, Paulo Maciag, Martine Amiot & Philippe Moreau Leukemia 2018 32 :1899 - 1907; August 03, 2018; 10.1038/s41375-018-0223-9   Abstract | Full Text Article Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis Christopher Maximilian Arends, Joel Galan-Sousa, Kaja Hoyer, Willy Chan, Marten Jäger et al. Leukemia 2018 32 :1908 - 1919; March 01, 2018; 10.1038/s41375-018-0047-7   Abstract | Full Text Novel evidence that extracellular nucleotides and purinergic signaling induce innate immunity-mediated mobilization of hematopoietic stem/progenitor cells Mateusz Adamiak, Kamila Bujko, Monika Cymer, Monika Plonka, Talita Glaser et al. Leukemia 2018 32 :1920 - 1931; March 30, 2018; 10.1038/s41375-018-0122-0   Abstract | Full Text Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors Jooeun Bae, Teru Hideshima, Yu-Tzu Tai, Yan Song, Paul Richardson et al. Leukemia 2018 32 :1932 - 1947; February 22, 2018; 10.1038/s41375-018-0062-8   Abstract | Full Text Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity Nicola Amodio, Maria Angelica Stamato, Giada Juli, Eugenio Morelli, Mariateresa Fulciniti et al. Leukemia 2018 32 :1948 - 1957; February 22, 2018; 10.1038/s41375-018-0067-3   Abstract | Full Text Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration Ahmed Y. Ali, Xun Wu, Nour Eissa, Sen Hou, Jean-Eric Ghia et al. Leukemia 2018 32 :1958 - 1969; January 31, 2018; 10.1038/s41375-018-0012-5   Abstract | Full Text An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies Matthew L Cooper, Jaebok Choi, Karl Staser, Julie K Ritchey, Jessica M Devenport et al. Leukemia 2018 32 :1970 - 1983; February 20, 2018; 10.1038/s41375-018-0065-5   Abstract | Full Text The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia Caroline L Furness, Marcela B Mansur, Victoria J Weston, Luca Ermini, Frederik W van Delft et al. Leukemia 2018 32 :1984 - 1993; March 20, 2018; 10.1038/s41375-018-0046-8   Abstract | Full Text The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma Nikolai Schleussner, Olaf Merkel, Mariantonia Costanza, Huan-Chang Liang, Franziska Hummel et al. Leukemia 2018 32 :1994 - 2007; March 28, 2018; 10.1038/s41375-018-0045-9   Abstract | Full Text Brief Communication Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations Christophe Willekens, Aline Renneville, Sophie Broutin, Véronique Saada, Jean-Baptiste Micol et al. Leukemia 2018 32 :2008 - 2081; February 26, 2018; 10.1038/s41375-018-0056-6   Abstract | Full Text TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells Dan Li, Yutian Hu, Zhen Jin, You Zhai, Yuting Tan et al. Leukemia 2018 32 :2012 - 2016; July 25, 2018; 10.1038/s41375-018-0212-z   Abstract | Full Text Identification of immune-activated hematopoietic stem cells Nir Bujanover, Oron Goldstein, Yariv Greenshpan, Hodaya Turgeman, Amit Klainberger et al. Leukemia 2018 32 :2016 - 2020; July 24, 2018; 10.1038/s41375-018-0220-z   Abstract | Full Text Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation Sneha Chitre, Friedrich Stölzel, Kirsty Cuthill, Mathew Streetly, Charlotte Graham et al. Leukemia 2018 32 :2020 - 2024; July 19, 2018; 10.1038/s41375-018-0208-8   Abstract | Full Text Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia Stephen E. Kurtz, Christopher A. Eide, Andy Kaempf, Motomi Mori, Cristina E. Tognon et al. Leukemia 2018 32 :2025 - 2028; August 06, 2018; 10.1038/s41375-018-0225-7   Abstract | Full Text Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels Gabriela Pavlasova, Marek Borsky, Veronika Svobodova, Jan Oppelt, Katerina Cerna et al. Leukemia 2018 32 :2028 - 2031; July 20, 2018; 10.1038/s41375-018-0211-0   Abstract | Full Text Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1 Laurent Garderet, Jacob P. Laubach, Anne-Marie Stoppa, Parameswaran Hari, Michele Cavo et al. Leukemia 2018 32 :2032 - 2036; March 12, 2018; 10.1038/s41375-018-0091-3   Abstract | Full Text YAP and TAZ are dispensable for physiological and malignant haematopoiesis Elisa Donato, Francesca Biagioni, Andrea Bisso, Marieta Caganova, Bruno Amati et al. Leukemia 2018 32 :2037 - 2040; March 26, 2018; 10.1038/s41375-018-0111-3   Abstract | Full Text A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells Wei Du, Wei Liu, Benjamin Mizukawa, Xun Shang, Jared Sipple et al. Leukemia 2018 32 :2041 - 2046; June 29, 2018; 10.1038/s41375-018-0200-3   Abstract | Full Text Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia Thomas Ernst, Melinda Busch, Jenny Rinke, Jana Ernst, Claudia Haferlach et al. Leukemia 2018 32 :2046 - 2049; June 13, 2018; 10.1038/s41375-018-0157-2   Abstract | Full Text Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective Hein Than, Yi Qiao, Xiaomeng Huang, Dongqing Yan, Jamshid S. Khorashad et al. Leukemia 2018 32 :2049 - 2054; March 27, 2018; 10.1038/s41375-018-0050-z   Abstract | Full Text Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014 Sissel Helm-Petersen, Rasmus Sørrig, Tobias W. Klausen, Birgitte Preiss, Ulf Christian Frølund et al. Leukemia 2018 32 :2054 - 2057; February 22, 2018; 10.1038/s41375-018-0057-5   Abstract | Full Text Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia Kristina B. Lundin-Ström, Andrea Biloglav, Henrik Lilljebjörn, Marianne Rissler, Thoas Fioretos et al. Leukemia 2018 32 :2058 - 2062; July 02, 2018; 10.1038/s41375-018-0191-0   Abstract | Full Text Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts Anne Buffière, Théo Accogli, Laetitia Saint-Paul, Géraldine Lucchi, Benjamin Uzan et al. Leukemia 2018 32 :2062 - 2065; February 28, 2018; 10.1038/s41375-018-0081-5   Abstract | Full Text Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia Aline Renneville, Philippe Attias, Xavier Thomas, Cécile Bally, Sandrine Hayette et al. Leukemia 2018 32 :2066 - 2069; April 18, 2018; 10.1038/s41375-018-0137-6   Abstract | Full Text Prognostic implication of appendicular skeleton bone marrow abnormalities detected using low-dose multidetector computed tomography in patients with myelodysplastic syndrome Yoshiaki Abe, Tomotaka Ugai, Manabu Fujisawa, Yuya Matsue, Kentaro Narita et al. Leukemia 2018 32 :2069 - 2073; March 07, 2018; 10.1038/s41375-018-0048-6   Abstract | Full Text PGC-1α driven mitochondrial biogenesis in stromal cells underpins mitochondrial trafficking to leukemic blasts Christopher R. Marlein, Lyubov Zaitseva, Rachel E. Piddock, Livia Raso-Barnett, Michael A. Scott et al. Leukemia 2018 32 :2073 - 2077; July 20, 2018; 10.1038/s41375-018-0221-y   Abstract | Full Text Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera Tiziano Barbui, Francesco Passamonti, Patrizia Accorsi, Fabrizio Pane, Alessandro M. Vannucchi et al. Leukemia 2018 32 :2077 - 2081; June 28, 2018; 10.1038/s41375-018-0199-5   Abstract | Full Text Correspondence The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor Carlos Fernández de Larrea, Ignacio Isola, Arturo Pereira, Ma Teresa Cibeira, Joan Bladé et al. Leukemia 2018 32 :2082 - 2094; May 23, 2018; 10.1038/s41375-018-0156-3   Abstract | Full Text Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression' Arjun Lakshman, Praful Ravi, S. Vincent Rajkumar & Shaji K. Kumar Leukemia 2018 32 :2083 - 2085; May 25, 2018; 10.1038/s41375-018-0155-4   Abstract | Full Text Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions Florian H. Heidel, Haifa-Kathrin Al-Ali, Carsten Hirt, Dietrich Kämpfe, Kathleen Jentsch-Ullrich et al. Leukemia 2018 32 :2085 - 2087; July 24, 2018; 10.1038/s41375-018-0214-x   Abstract | Full Text Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway Lijuan Han, Julia Czech, Angela Maurer, Tim H. Brümmendorf, Nicolas Chatain et al. Leukemia 2018 32 :2087 - 2090; August 08, 2018; 10.1038/s41375-018-0234-6   Abstract | Full Text Comment on structural basis of DUX4/IGH-driven transactivation Hideki Aihara, Ke Shi, John K. Lee, Darko Bosnakovski & Michael Kyba Leukemia 2018 32 :2090 - 2092; July 27, 2018; 10.1038/s41375-018-0217-7   Abstract | Full Text Blast-phase chronic myelomonocytic leukemia: more than just semantics Mrinal M. Patnaik, Ayalew Tefferi & Guillermo Garcia-Manero Leukemia 2018 32 :2093 - 2094; August 07, 2018; 10.1038/s41375-018-0228-4   Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.